Company
Angiex
Exploiting novel biology to gain revolutionary power over cancer
- Status
- Operatingas of 2026-09-20Source (opens in a new tab)
- Business model
- B2B
- angiex.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies to all.
Funding snapshot
- Total raised
- $31MSum of rounds, as of 2026-09-20Source (opens in a new tab)
- Latest round
- Undisclosed, $31M2025-11-14
Funding rounds
- Round, 2025
- $31M2025-11-14, Company stated
- Round, 2025
- $22M2025-07-31, SEC form D sold, 137 investors
- Round, 2017
- $2.9M2017-07-03, SEC form D sold, 3 investors
Products
- Other
- AGX101
Loading relationship preview